Palbociclib in hormone-receptor-positive advanced breast cancer

New England Journal of Medicine

Volumn 373, Issue 3, 2015, Pages 209-219

  Turner, Nicholas C ^a   Ro, Jungsil ^b   André, Fabrice ^c   Loi, Sherene ^d   Verma, Sunil ^e   Iwata, Hiroji ^f   Harbeck, Nadia ^g   Loibl, Sibylle ^h   Bartlett, Cynthia Huang ⁱ   Zhang, Ke ⁱ   Giorgetti, Carla ^j   Randolph, Sophia ⁱ   Koehler, Maria ⁱ   Cristofanilli, Massimo ^i,k  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b National Cancer Center   (South Korea)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^f AICHI CANCER CENTER HOSPITAL   (Japan)

^g UNIVERSITY OF MUNICH   (Germany)

^h German Breast Group   (Germany)

ⁱ PFIZER INC   (United States)

^j Milan ^*  (Italy)

^k THOMAS JEFFERSON UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FULVESTRANT; PALBOCICLIB; PLACEBO; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CDK4 PROTEIN, HUMAN; CDK6 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; ERBB2 PROTEIN, HUMAN; ESTRADIOL; ESTROGEN RECEPTOR; PIPERAZINE DERIVATIVE; PROGESTERONE RECEPTOR; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; BACKACHE; BREAST CANCER; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEADACHE; HOT FLUSH; HUMAN; INCREASED APPETITE; LEUKOPENIA; MAJOR CLINICAL STUDY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VOMITING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; MIDDLE AGED; MULTICENTER STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; ESTRADIOL; FEMALE; HUMANS; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIDINES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84937042338     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1505270     Document Type: Article

References (25)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-717.
2. Baselga J, Campone M, Piccart M., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366: 520-9.
3. Klijn JG, Beex LV, Mauriac L, et al Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst 2000; 92:903-11.
4. Di Leo A., Jerusalem G, Petruzelka L., et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010; 28:4594-600.
5. Di Leo A., Jerusalem G, Petruzelka L., et al. Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst 2014; 106:djt337.
6. Asghar U, Witkiewicz AK, Turner N.C., Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov 2015; 14:130-46.
7. Musgrove EA, Caldon CE, Barraclough J, Stone A., Sutherland RL. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 2011; 11:558-72.
8. Yu Q, Sicinska E, Geng Y., et al. Requirement for CDK4 kinase function in breast cancer. Cancer Cell 2006; 9: 23-32.
9. Miller TW, Balko JM, Fox E.M., et al. ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov 2011; 1:338-51.
10. Thangavel C, Dean JL, Ertel A, et al Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer 2011; 18:333-45.
11. Toogood PL, Harvey PJ, Repine J.T., et al. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J Med Chem 2005; 48:2388-406.
12. Finn RS, Dering J, Conklin D., et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 2009; 11: R77.
13. DeMichele A, Clark AS, Tan K.S., et al. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment. Clin Cancer Res 2015; 21: 995-1001.
14. Finn RS, Crown JP, Lang I, et al The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 2015; 16: 25-35.
15. Eisenhauer EA, Therasse P, Bogaerts J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
16. Haybittle JL. Repeated assessment of results in clinical trials of cancer treatment. Br J Radiol 1971; 44: 793-7.
17. Zhang JJ, Zhang L, Chen H., et al. Assessment of audit methodologies for bias evaluation of tumor progression in oncology clinical trials. Clin Cancer Res 2013; 19: 2637-45.
18. Schiff R, Massarweh SA, Shou J, Bharwani L., Mohsin SK, Osborne CK. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 2004; 10: 331S-6S.
19. Miller TW, Hennessy BT, González-Angulo AM, et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 2010; 120: 2406-13.
20. Toy W, Shen Y, Won H., et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet 2013; 45:1439-45.
21. Robinson DR, Wu YM, Vats P, et al Activating ESR1 mutations in hormoneresistant metastatic breast cancer. Nat Genet 2013; 45:1446-51.
22. Mehta RS, Barlow WE, Albain K.S., et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 2012; 367:435-44.
23. Francis PA, Regan MM, Fleming G.F., et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 2015; 372:436-46.
24. Park IH, Ro J, Lee K.S., et al. Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy. J Clin Oncol 2010; 28:2705-11.
25. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology (NCCN Guidelines): breast cancer - version 2. 2015 (http://www.nccn.org/professionals/physician-gls/f-guidelines.asp).